Incretin hormone mimetics and analogues in diabetes therapeutics

Brian D. Green; Peter Flatt

doi:10.1016/i.beem.2007.09.003

Incretin hormone mimetics and analogues in diabetes therapeutics

Brian D. Green, Peter Flatt

Research output: Contribution to journal › Article › peer-review

92 Citations (Scopus)

Abstract

The incretin hormones glucagon-like peptide-I (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are physiological gut peptides with insulin-releasing and extrapancreatic glucoregulatory actions. Incretin analogues/mimetics activate GLP-I or GIP receptors whilst avoiding physiological inactivation by dipeptidyl peptidase 4 (DPP-4), and they represent one of the newest classes of antidiabetic drug. The first clinically approved GLP-1 mimetic for the treatment of type-2 diabetes is exenatide (Byetta/exendin) which is administered subcutaneously twice daily. Clinical trials of liraglutide, a GLP-1 analogue suitable for once-daily administration, are ongoing. A number of other incretin molecules are at earlier stages of development. This review discusses the various attributes of GLP-1 and GIP for diabetes treatment and summarises current clinical data. Additionally, it explores the therapeutic possibilities offered by preclinical agents, such as non-peptide GLP-1 mimetics, GLP-1/glucagon hybrid peptides, and specific GIP receptor antagonists.

Original language	English
Pages (from-to)	497-516
Journal	Best Practice and Research: Clinical Endocrinology and Metabolism
Volume	21
Issue number	4
DOIs	https://doi.org/10.1016/i.beem.2007.09.003
Publication status	Published (in print/issue) - Dec 2007

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/i.beem.2007.09.003

Cite this

@article{ce245c0ab15f47bfa1289c32f73f5d2d,

title = "Incretin hormone mimetics and analogues in diabetes therapeutics",

abstract = "The incretin hormones glucagon-like peptide-I (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are physiological gut peptides with insulin-releasing and extrapancreatic glucoregulatory actions. Incretin analogues/mimetics activate GLP-I or GIP receptors whilst avoiding physiological inactivation by dipeptidyl peptidase 4 (DPP-4), and they represent one of the newest classes of antidiabetic drug. The first clinically approved GLP-1 mimetic for the treatment of type-2 diabetes is exenatide (Byetta/exendin) which is administered subcutaneously twice daily. Clinical trials of liraglutide, a GLP-1 analogue suitable for once-daily administration, are ongoing. A number of other incretin molecules are at earlier stages of development. This review discusses the various attributes of GLP-1 and GIP for diabetes treatment and summarises current clinical data. Additionally, it explores the therapeutic possibilities offered by preclinical agents, such as non-peptide GLP-1 mimetics, GLP-1/glucagon hybrid peptides, and specific GIP receptor antagonists.",

author = "Green, {Brian D.} and Peter Flatt",

year = "2007",

month = dec,

doi = "10.1016/i.beem.2007.09.003",

language = "English",

volume = "21",

pages = "497--516",

journal = "Best Practice and Research: Clinical Endocrinology and Metabolism",

publisher = "Elsevier",

number = "4",

}

TY - JOUR

T1 - Incretin hormone mimetics and analogues in diabetes therapeutics

AU - Green, Brian D.

AU - Flatt, Peter

PY - 2007/12

Y1 - 2007/12

N2 - The incretin hormones glucagon-like peptide-I (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are physiological gut peptides with insulin-releasing and extrapancreatic glucoregulatory actions. Incretin analogues/mimetics activate GLP-I or GIP receptors whilst avoiding physiological inactivation by dipeptidyl peptidase 4 (DPP-4), and they represent one of the newest classes of antidiabetic drug. The first clinically approved GLP-1 mimetic for the treatment of type-2 diabetes is exenatide (Byetta/exendin) which is administered subcutaneously twice daily. Clinical trials of liraglutide, a GLP-1 analogue suitable for once-daily administration, are ongoing. A number of other incretin molecules are at earlier stages of development. This review discusses the various attributes of GLP-1 and GIP for diabetes treatment and summarises current clinical data. Additionally, it explores the therapeutic possibilities offered by preclinical agents, such as non-peptide GLP-1 mimetics, GLP-1/glucagon hybrid peptides, and specific GIP receptor antagonists.

AB - The incretin hormones glucagon-like peptide-I (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are physiological gut peptides with insulin-releasing and extrapancreatic glucoregulatory actions. Incretin analogues/mimetics activate GLP-I or GIP receptors whilst avoiding physiological inactivation by dipeptidyl peptidase 4 (DPP-4), and they represent one of the newest classes of antidiabetic drug. The first clinically approved GLP-1 mimetic for the treatment of type-2 diabetes is exenatide (Byetta/exendin) which is administered subcutaneously twice daily. Clinical trials of liraglutide, a GLP-1 analogue suitable for once-daily administration, are ongoing. A number of other incretin molecules are at earlier stages of development. This review discusses the various attributes of GLP-1 and GIP for diabetes treatment and summarises current clinical data. Additionally, it explores the therapeutic possibilities offered by preclinical agents, such as non-peptide GLP-1 mimetics, GLP-1/glucagon hybrid peptides, and specific GIP receptor antagonists.

U2 - 10.1016/i.beem.2007.09.003

DO - 10.1016/i.beem.2007.09.003

M3 - Article

VL - 21

SP - 497

EP - 516

JO - Best Practice and Research: Clinical Endocrinology and Metabolism

JF - Best Practice and Research: Clinical Endocrinology and Metabolism

IS - 4

ER -

Incretin hormone mimetics and analogues in diabetes therapeutics

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this